SGT 001

Drug Profile

SGT 001

Alternative Names: SGT-001

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Missouri-Columbia
  • Developer Solid GT; University of Missouri-Columbia
  • Class Gene therapies
  • Mechanism of Action Dystrophin expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 30 Nov 2017 The US FDA grants Rare Pediatric Disease Designation status to SGT 001 for Duchenne muscular dystrophy
  • 12 Oct 2017 The US FDA approves IND application for SGT 001 in Duchenne muscular dystrophy
  • 08 Jun 2017 Solid Biosciences plans an adaptive phase I/II trial to evaluate the safety and efficacy of intravenous SGT 001 for Duchenne muscular dystrophy in USA, in the second half of 2017 (Solid Biosciences website, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top